Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + TP as neoadjuvant therapy for HNSCC
NCT06895369Phase 2Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Sir Run-Run Shaw Hospital. Planned start May 2025; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06895369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895369.